by John Conrad | May 12, 2025 | Policy News
“The President’s Most Favored Nation proposal represents a catastrophic misstep for American biosciences innovation and patient access to life-saving treatments,” said John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization. “This...
by John Conrad | Apr 16, 2025 | Policy News
iBIO recognizes the significance of the Trump Administration’s recent Executive Order addressing drug pricing in the United States. We particularly welcome the Administration’s acknowledgment of the “pill penalty” issue and examination of PBM...
by John Conrad | Jan 8, 2025 | Grants, NewsBrief
In partnership with G2G Consulting, we are please to provide the January 2025 Grants report, showcasing 196 non-dilutive government funding opportunities across diverse biomedical and life sciences sectors. The comprehensive report underscores significant funding...
by John Conrad | Dec 18, 2024 | iBIO in the News
iBIO President & CEO John Conrad recently had the pleasure of chatting with Kyle LaHucik to discuss the exciting developments in our biotech ecosystem. Many of you may have already seen his excellent article published yesterday in Endpoints News, which provides a...
by John Conrad | Sep 25, 2024 | NewsBrief
PCI Pharma Services is set to significantly expand its presence in Rockford, Illinois, as part of a broader $365 million investment across its U.S. and European operations. The contract development and manufacturing organization (CDMO) announced on Tuesday, September...
